Cargando…

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Detalles Bibliográficos
Autores principales:	Tian, Xinyu, Zheng, Xiangyun, Tian, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587137/ https://www.ncbi.nlm.nih.gov/pubmed/37857611 http://dx.doi.org/10.1038/s41392-023-01643-w

Ejemplares similares

Cytotoxic FCER1G(+) innate-like T cells: new potential for tumour immunotherapy
por: Morrish, Emma, et al.
Publicado: (2022)

An anti-tumor coup: TIM3 ablation activates the immune arsenal
por: Görgülü, Kıvanç, et al.
Publicado: (2021)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
por: Fu, Caiyun
Publicado: (2020)

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
por: Valente, Sofia, et al.
Publicado: (2023)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Deletion of the RNA-editing enzyme ADAR1A: new strategy to potentiate responses to PD-1 immune checkpoint blockade
por: Wang, Manni, et al.
Publicado: (2019)

Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors
por: Alkan, Fulya Koksalar, et al.
Publicado: (2020)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
por: Cao, Yuqing, et al.
Publicado: (2020)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Tumour travel tours – Why circulating cancer cells value company
por: Häfner, Sophia Julia
Publicado: (2020)

The determinants associated with zoonotic potential of influenza A viruses: BTN3A3 evasion mediated by residue mutation in the nucleoprotein
por: Tian, Lili, et al.
Publicado: (2023)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
por: Quatrini, Linda, et al.
Publicado: (2020)

Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
por: Merino‐Vico, Ana, et al.
Publicado: (2022)

Histamine and histamine receptor H1 (HRH1) axis: new target for enhancing immunotherapy response
por: Bai, Ziyi, et al.
Publicado: (2022)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

Regenerative potential of targeting glycogen synthase kinase-3 signaling in neural tissues
por: Jung, Eui-Man, et al.
Publicado: (2015)

EphB2: potential therapeutic target for Alzheimer’s disease
Publicado: (2011)

CIMBL55: a repository for maize drought resistance alleles
por: Tian, Tian, et al.
Publicado: (2023)

An effective platform for cancer immunotherapy: pooled knockin targeting for genome engineering
por: Jin, Ke, et al.
Publicado: (2020)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
por: Almeida, Catarina R., et al.
Publicado: (2021)

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy
por: Du, Songtao, et al.
Publicado: (2023)

CAR-T: a potential gene carrier targeting solid tumor immune microenvironment
por: Wang, Minjie, et al.
Publicado: (2021)

Research on ADR1s helps understanding the plant immune network
por: Hu, Meijuan, et al.
Publicado: (2022)

Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy
por: Nüse, Björn, et al.
Publicado: (2022)

Targeting α7 nicotinic acetylcholine receptors: a future potential for neuroprotection from traumatic brain injury
por: Shin, Samuel S., et al.
Publicado: (2015)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Recognition of Salmonella by Dectin-1 induces presentation of peptide antigen to type B T cells
por: Jackson, Nicola, et al.
Publicado: (2014)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy
por: Bai, Xinyu, et al.
Publicado: (2022)

FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
por: He, Xuemei, et al.
Publicado: (2021)

Active zone stability: insights from fly neuromuscular junction
por: Tian, Xiaolin, et al.
Publicado: (2015)

The many (sur)faces of B cells
por: Häfner, Sophia Julia
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cekqvoh57fid2vpf1ijn4d3aq6